חיפוש מתקדם
Transplantation
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel, Institute of Animal Science, ARO, Volcani Center, Bet Dagan 50250, Israel
Background. In chronic graft-versus-host disease (cGvHD), skin fibrosis, contractures, and an increase in collagen content form the hallmark. We report a successful treatment of a cGvHD patient by topical application of halofuginone, an inhibitor of collagen α1(I) gene expression. Methods. Halofuginone-containing ointment was applied daily on the left side of the neck and shoulder of a cGvHD patient. Collagen α1(I) gene expression and collagen content in skin biopsy specimens were evaluated by in situ hybridization and sirius red staining, respectively. Results. After 3 and 6 months, a marked reduction in skin collagen synthesis was observed, accompanied with increase neck rotation on the treated side. After cessation of treatment, the sclerosis, skin tightness, and collagen α1(I) gene expression returned to baseline level. No adverse effects were observed, and no plasma levels of halofuginone could be detected. Conclusions. Halofuginone may provide a promising novel and safe therapy for cGvHD patients.
פותח על ידי קלירמאש פתרונות בע"מ -
הספר "אוצר וולקני"
אודות
תנאי שימוש
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: A novel inhibitor of collagen type I synthesis
68
Nagler, A., Dept. of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
Pines, M., Institute of Animal Science, Agricultural Research Organization, Volcani Center, Bet Dagan, Israel, Institute of Animal Science, ARO, Volcani Center, Bet Dagan 50250, Israel
Topical treatment of cutaneous chronic graft versus host disease with halofuginone: A novel inhibitor of collagen type I synthesis
Background. In chronic graft-versus-host disease (cGvHD), skin fibrosis, contractures, and an increase in collagen content form the hallmark. We report a successful treatment of a cGvHD patient by topical application of halofuginone, an inhibitor of collagen α1(I) gene expression. Methods. Halofuginone-containing ointment was applied daily on the left side of the neck and shoulder of a cGvHD patient. Collagen α1(I) gene expression and collagen content in skin biopsy specimens were evaluated by in situ hybridization and sirius red staining, respectively. Results. After 3 and 6 months, a marked reduction in skin collagen synthesis was observed, accompanied with increase neck rotation on the treated side. After cessation of treatment, the sclerosis, skin tightness, and collagen α1(I) gene expression returned to baseline level. No adverse effects were observed, and no plasma levels of halofuginone could be detected. Conclusions. Halofuginone may provide a promising novel and safe therapy for cGvHD patients.
Scientific Publication
You may also be interested in